Clinical Trials Logo

Filter by:
NCT ID: NCT00231114 Completed - Asthma Clinical Trials

Asthma Intervention Research 2 (AIR2) Trial

Start date: September 2005
Phase: N/A
Study type: Interventional

The objective of this randomized, double blind, sham-controlled study is to demonstrate the safety and effectiveness of the Alair System in a population of subjects with severe asthma who are still symptomatic despite being managed on conventional therapy of high doses of inhaled corticosteroids and long-acting β2-agonists. The primary efficacy endpoint will be the difference between Study groups in the change in Asthma Quality of Life Questionnaire (AQLQ) score from Baseline and the average score from the 6-, 9-, and 12-month follow-up visits. All other outcome measures assessed at 12 months post-treatment. This will be a multicenter, randomized, double-blind, sham-controlled study comparing the effects of treatment with the Alair System to conventional therapy of inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA). A Bayesian adaptive approach to sample size selection is used with a randomization scheme of 2:1 (two Alair Group Subjects for every one Control Group Subject).

NCT ID: NCT00230971 Completed - Appendicitis Clinical Trials

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)

Start date: October 2005
Phase: Phase 4
Study type: Interventional

This is a study of the safety and efficacy of tigecycline to ceftriaxone sodium plus metronidazole in hospitalized subjects with cIAI. Subjects will be followed for efficacy through the test-of-cure assessment. Safety evaluations will occur through the treatment and post-treatment periods and continue through resolution or stability of the adverse event(s).

NCT ID: NCT00229697 Completed - Breast Neoplasms Clinical Trials

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Start date: October 2003
Phase: Phase 2
Study type: Interventional

This study is being carried out to see if ZD1839 is effective in treating metastatic breast cancer in combination with Nolvadex, and if so, how it compares with Nolvadex alone.

NCT ID: NCT00228657 Completed - Length of ICU Stay Clinical Trials

Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride

Start date: July 2002
Phase: Phase 1/Phase 2
Study type: Interventional

Patients resuscitated with 4% Albumin will have less incidence and reduced severity of pressure injuries than patients resuscitated with 0.9% Sodium Chloride due to the improved intravascular oncotic pressure effected from higher albumin levels.

NCT ID: NCT00228553 Completed - Narcolepsy Clinical Trials

Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness

Start date: May 2004
Phase: Phase 3
Study type: Interventional

A 12 Month, Open-Label, Flexible Dosage Extension Study of the Safety and Efficacy of Armodafinil (CEP-10953) in the Treatment of Patients with Excessive Sleepiness Associated with Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

NCT ID: NCT00227500 Completed - HIV Infections Clinical Trials

Pravastatin for Hyperlipidaemia in HIV.

Start date: July 2001
Phase: Phase 4
Study type: Interventional

This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.

NCT ID: NCT00226902 Completed - Clinical trials for Diabetes Mellitus, Type 2

Vascular Reactivity in Kidney Disease Patients

Start date: September 2006
Phase: N/A
Study type: Interventional

Dialysis patients suffer from many problems with blood vessels and this is even more so for patients with the added complication of diabetes. Diabetics have a number of reasons for vascular disease and one of the new areas of research is looking at the cells that line the blood vessels, called endothelial cells. It is thought that the number of red blood cells in the blood (haemoglobin concentration) affects the function of these cells. There is very little information available on what haemoglobin level is best for dialysis patients. As diabetics account for almost 40% of dialysis patients worldwide it is important to understand the effect different haemoglobin levels will have on the blood vessels. Hypothesis: Endothelial cell function and the related expansile capacity of blood vessels are affected by different haemoglobin concentrations [Hb] in dialysis patients.

NCT ID: NCT00226876 Completed - Anaesthesia Clinical Trials

Dreaming During Anaesthesia and Anaesthetic Depth

Start date: February 2005
Phase: N/A
Study type: Observational

Patients commonly report that they have been dreaming when they awaken from general anaesthesia. Our hypothesis is that patients who report dreaming are less deeply anaesthetised during anaesthesia than patients who do not report dreaming. Depth of anaesthesia will be determined using a processed electroencephalographic monitor (called the BIS monitor).

NCT ID: NCT00226837 Completed - Clinical trials for Depth of Anaesthesia

Quantifying Nitrous Oxide Effect on Depth of Anaesthesia Using Theoretically Based Time Series Modelling

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Our hypothesis is that a new method of depth of anaesthesia monitoring, using theoretically based time series modelling will result in improved ability to determine nitrous oxide anaesthetic effect

NCT ID: NCT00226096 Completed - Clinical trials for Intracranial Hemorrhages

Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Start date: November 2005
Phase: N/A
Study type: Interventional

The purpose of the study is to determine whether lowering high blood pressure levels after the start of a stroke caused by bleeding in the brain (intracerebral haemorrhage) will reduce the chances of a person dying or surviving with a long term disability. The study will be undertaken in two phases: a vanguard phase in 400 patients, to plan for a main phase in 2000 patients.